Standalone Unaudited Financial Results for the 1st Quarter ended 30th June 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board approved standalone unaudited results for Q1 FY26 (ended 30 June 2025), reporting revenue from operations of ₹29,991.45 lacs and a profit after tax of ₹2,329.94 lacs (EPS ₹2.07), compared to a loss of ₹34.48 lacs in Q1 FY25. The revenue jump is driven by a complete business pivot — the company has shifted its operations from 'Dealing in Medical Products' (₹0 revenue this quarter) to 'Trading in Agriculture Produce' (entire ₹29,991 lacs). The corporate office is being relocated within Ahmedabad from Jagatpur to C.G. Road, Ellisbridge. Three new directors (Mr. Ravi Thakor, Mr. Yogeshkumar Prajapati, Mrs. Bhumika Pradhan) were appointed, while two existing directors (Mr. Suraj Solanki and Mrs. Deepika Iyer) resigned citing pre-occupation, leading to a full reconstitution of the Audit, Nomination & Remuneration, and Stakeholders Relationship committees.
Shareholders should note that the statutory auditor issued a Disclaimer of Opinion, flagging major concerns including unconfirmed receivables and payables, missing E-Way bills/delivery documentation, no goods inward register, and inability to verify inventory — meaning the reported profits are not independently verified. The dramatic segment switch and the auditor's disclaimer raise serious red flags about the quality and reliability of these numbers despite the headline PAT turnaround.